Clinical trials
Staphylococcal Infections trials in the United States with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
21 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Terminated | 2 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Henry M. Jackson Foundation for the Advancement of Military Medicine | 3 |
| Washington University School of Medicine | 3 |
| University of Maryland, Baltimore | 2 |
| Ann & Robert H Lurie Children's Hospital of Chicago | 1 |
| Baylor College of Medicine | 1 |
| Bristol-Myers Squibb | 1 |
| Brooke Army Medical Center | 1 |
| Christiana Care Health Services | 1 |
| Johns Hopkins University | 1 |
| Lucy Holmes, MD | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Staphylococcal Infections | 21 |
| Abscess | 6 |
| Staphylococcal Skin Infections | 5 |
| Furunculosis | 4 |
| Cross Infection | 3 |
| Candidemia | 1 |
| Cellulitis | 1 |
| Communicable Diseases | 1 |
| Community-Acquired Infections | 1 |
| Dermatitis, Atopic | 1 |
Trials
Showing 1 to 21 of 21. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.